The Oxford Corona vaccine was given to these two people in India

New delhi date. 27 August 2020, Thursday

A worldwide trial of the corona virus vaccine has begun. Meanwhile, Oxford University in India has also started a second and third stage clinical trial. The trial was started at Bharti Hospital in Pune, where two people were given the first dose. One of the 48-year-old volunteers is a gynecologist at a private hospital in Pune, while the other volunteer is a 32-year-old doctor. Who works in a private company.

The first dose of the vaccine was given to a 32-year-old volunteer on Wednesday at 1:35 p.m., while the second volunteer was given the vaccine 15 minutes later at 1:50 p.m. The 48-year-old gynecologist who administered the dose of the Covishield vaccine in Oxford volunteered for the swine flu vaccine 10 years ago as a volunteer.

A huge crowd of volunteers was seen during the vaccine trial. 250-300 volunteers gathered at 4 places in Pune. Out of which some people were nominated for screening. "I'm not excited about taking part in this trial because I've seen so many people die from the virus," said the gynecologist who administered the vaccine. Vaccines are the only cure for the virus.

Dr. Asmita Jagtap, Executive Director, Department of Health Sciences, Bharti Vidyapeeth, said that the institute has conducted more than 50 clinical trials in the last 15 years. "We have received many such calls," he said. Who wanted to participate as volunteers.

The vaccine has been tested on 1600 people. The Drug Controller General of India and the National Drug Regulator had on August 3 approved the second and third human clinical trials of the vaccine in India at the Serum Institute of India in Pune.

Human clinical trials of the ChAdOx1 nCoV-19 vaccine are already underway in Brazil, South Africa and the UK. The University of Oxford announced to researchers last month that the immune response to the vaccine had been doubled in a trial and that it was completely safe.

The Oxford University vaccine is designed to weaken a common cold virus, which does not develop in people. The Serum Institute of India has reached an agreement with AstraZeneca to produce one billion vaccines for this vaccine for low-population countries.